Wednesday, June 20, 2018

The Next Frontier in Cancer Care

Value has become a central topic in any debate regarding cancer care in Greece and abroad, for a simple reason: reality has caught up with us. Costs and treatment innovations are conflicting realities that force the oncology community to adopt value-based solutions to a system in crisis. On one side, the pace of innovation in oncology is tremendous and unprecedented: newly approved drugs abound; precision oncology and immunotherapy are gradually becoming a reality; and patients are having access to an increasing number of treatment options that help them live longer with better quality of life. On the other side, the costs to treat cancer are astronomical and continue to increase, threatening our own ability to provide cancer care and causing financial harm to patients.

Early Bird

Conference’s Scope

The conference, now in its fourth year, is a forum for discussion for government representatives, academic society, physicians, patients, researchers, and pharmaceutical industry executives, to discuss innovative therapeutic approaches and cost-effective measures to the benefit of healthcare system and patients. The scope of the conference is to explore opportunities for greater multi-stakeholder cooperation and a more integrated approach to cancer care as key drivers to deliver sustainable and high-value care for patients. Best practices at a national and international level will contribute to the dialogue aiming at significantly improving cancer patient outcomes, fostering innovative research approaches, intensifying cancer prevention research efforts, and reducing the financial burden targeted to this disease.

This year the special theme of the conference is the next frontier in cancer care that aims to showcase the most innovative methods of treatment, while at the same time confronting the urgency to balance the delivery of high quality cancer care with costs. Cancer & Personalized Medicine Conference will offer a platform to discuss new models of care delivery and reimbursement that emphasize value.

Who should attend

  • Government representatives
  • National health system regulators and administrators
  • Academic Society
  • Consultants
  • Researchers
  • Radiologists
  • Chemotherapists
  • Pathologists
  • Patient Advocates and Patient Groups
  • Healthcare Industry representatives (Pharmaceutical Companies, Medical Devices Manufacturing Companies, Diagnostics Companies)
  • Students
  • Journalists

Key Issues

  • Cancer Policies and the Cost of Precenting, Researching and Treating Cancer
  • Innovation in Cancer Research & Treatment
  • Personalised and Targeted Therapies & the Use of Biomarkers
View more


Speakers include:

  • Government and National Health System Regulators and Administrators
  • Oncology Academics and Researchers
  • Health Economists and Health & Science Policy Specialists
  • Patient advocates & patient group representatives
  • Professional and industry association representatives
  • Cancer Associations and Societies representatives
  • Medical Oncologists
  • Industry Representatives

© 2018 Boussias Communications, all rights reserved., T:210 6617777, F:210 6617778

Designed by Boussias
New Media Team